IL-1β, TGF-β, and bradykinin, in human pulmonary artery smooth muscle, decreased the production of cAMP in response to subsequent administration of PGI2 analogues, providing data that inflammation can impair the actions of PGI2 analogues in pulmonary hypertension treatment [14]. Here, IL1B is linked to pulmonary arterial hypertension.